FDA clears Alleye AMD monitoring application

The FDA has issued 510(k) clearance of Alleye, a mobile medical software application, Oculocare medical announced in a press release.

Alleye is designed to detect and monitor age-related macular degeneration and characterize central and paracentral metamorphopsia, the release said.

“We are very excited about the FDA clearance, which will help millions of patients with AMD to better manage their health by monitoring their eyesight,” Lucas Bachmann, Oculocare CEO and co-founder, said in the release.

Oculocare is planning to market Alleye in the United States through pharmaceutical or medical technology partners.

The FDA has issued 510(k) clearance of Alleye, a mobile medical software application, Oculocare medical announced in a press release.

Alleye is designed to detect and monitor age-related macular degeneration and characterize central and paracentral metamorphopsia, the release said.

“We are very excited about the FDA clearance, which will help millions of patients with AMD to better manage their health by monitoring their eyesight,” Lucas Bachmann, Oculocare CEO and co-founder, said in the release.

Oculocare is planning to market Alleye in the United States through pharmaceutical or medical technology partners.